Author

J. Haanen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Guislain· 1 shared A. J. Morris· 1 shared A. Mazzocca· 1 shared A. Menegakis· 1 shared A. Perrakis· 1 shared A. Shahrabi· 1 shared A. Veenhof· 1 shared B. de Bruijn· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Guislain

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

S. M. Castenmiller, N. Kanagasabesan, A. Guislain, B. Nicolet, M. van Loenen, K. Monkhorst, A. Veenhof, E. Smit, K. Hartemink, J. Haanen, R. de Groot, M. Wolkers

This study identifies that high B cell infiltrates in NSCLC tumors, associated with tertiary lymphoid structures, negatively correlate with the tumor-reactivity of expanded TIL products.

bioRxiv · Feb 19, 2024Immunology

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells

E. Matas-Rico, E. Frijlink, I. van der Haar Avila, A. Menegakis, M. van Zon, A. J. Morris, J. Koster, F. Salgado-Polo, S. de Kivit, T. Lanca, A. Mazzocca, Z. Johnson, J. Haanen, T. N. Schumacher, A. Perrakis, , W. H. Moolenaar

This study shows that ATX secreted by melanoma cells repels CD8+ T cells, reducing their infiltration into tumors and impairing anti-tumor immunity.

bioRxiv · Feb 26, 2020Cancer Biology